Indeksa Nr.
|
Ķīmiskais nosaukums
|
EK Nr.
|
CAS Nr.
|
Klasifikācija
|
Marķējums
|
Specifiskās robežkoncentrācijas, m-koeficienti un ATE
|
Piezīmes
|
Bīstamības klases un kategorijas kods
|
Bīstamības apzīmējuma kods
|
Piktogrammas, signālvārda kods
|
Bīstamības apzīmējuma kods
|
Papildu bīstamības apzīmējuma kods
|
“014-052-00-7
|
silanamīns, 1,1,1-trimetil-N-(trimetilsilil)-, hidrolīzes ar silīciju produkti; pirogēnisks, sintētiski amorfs, silīcija dioksīds nanoformā ar apstrādātu virsmu
|
272-697-1
|
68909-20-6
|
STOT RE 2
|
H373 (plaušas) (ieelpojot)
|
GHS08
Wng
|
H373 (plaušas) (ieelpojot)
|
EUH066”
|
|
|
“035-005-00-7
|
amonija bromīds
|
235-183-8
|
12124-97-9
|
Repr. 1B
Lact.
STOT SE 3
STOT RE 1
Eye Irrit. 2
|
H360FD
H362
H336
H372 (nervu sistēma)
H319
|
GHS08
GHS07
Dgr
|
H360FD
H362
H336
H372 (nervu sistēma)
H319”
|
|
|
|
“050-032-00-4
|
dibutilalvas bis(2-etilheksanoāts)
|
220-481-2
|
2781-10-4
|
Muta. 2
Repr. 1B
STOT RE 1
|
H341
H360FD
H372 (imūnsistēma)
|
GHS08
Dgr
|
H341
H360FD
H372 (imūnsistēma)”
|
|
|
|
“050-033-00-X
|
dibutilalvas di(acetāts)
|
213-928-8
|
1067-33-0
|
Muta 2
Repr. 1B
STOT RE 1
|
H341
H360FD
H372 (imūnsistēma)
|
GHS08
Dgr
|
H341
H360FD
H372 (imūnsistēma)”
|
|
|
|
“052-001-00-0
|
telūrs
|
236-813-4
|
13494-80-9
|
Repr. 1B
Lact.
|
H360Df
H362
|
GHS08
Dgr
|
H360Df
H362”
|
|
|
|
“052-002-00-6
|
telūra dioksīds
|
231-193-1
|
7446-07-3
|
Repr. 1B
Lact.
|
H360Df
H362
|
GHS08
Dgr
|
H360Df
H362”
|
|
|
|
“056-005-00-3
|
bārija dibora tetraoksīds
|
237-222-4
|
13701-59-2
|
Repr. 1B
Acute Tox. 4
Acute Tox. 3
|
H360FD
H332
H301
|
GHS08
GHS06
Dgr
|
H360FD
H332
H301
|
|
ieelpojot:
ATE = 1,5 mg/L (putekļi vai aerosoli)
perorāli:
ATE = 100 mg uz kg ķermeņa masas”
|
|
“601-097-00-8
|
propilbenzols
|
203-132-9
|
103-65-1
|
Flam. Liq. 3
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2
|
H226
H304
H335
H411
|
GHS02
GHS08
GHS07
GHS09
Dgr
|
H226
H304
H335
H411”
|
|
|
|
“603-243-00-6
|
2,2-dimetilpropān-1-ols, tribromatvasinājums; 3-brom-2,2-bis(brommetil)propān-1-ols
|
253-057-0
|
36483-57-5; 1522-92-5
|
Carc. 1B
Muta. 2
|
H350
H341
|
GHS08
Dgr
|
H350
H341”
|
|
|
|
“604-096-00-0
|
piperonila butoksīds (ISO); 2-(2-butoksietoksi)etil-6-propilpiperonilēteris
|
200-076-7
|
51-03-6
|
STOT SE 3
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H335
H319
H400
H410
|
GHS07
GHS09
Wng
|
H335
H319
H410
|
EUH066
|
M = 1
M = 1”
|
|
“604-097-00-6
|
2,4,6-tri-terc-butilfenols
|
211-989-5
|
732-26-3
|
Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1B
|
H360D
H302
H373 (aknas)
H317
|
GHS08
GHS07
Dgr
|
H360D
H302
H373 (aknas)
H317
|
|
perorāli:
ATE = 500 mg uz kg ķermeņa masas”
|
|
“604-098-00-1
|
4,4’-sulfonildifenols; bisfenols S
|
201-250-5
|
80-09-1
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD”
|
|
|
|
“606-153-00-5
|
benzofenons
|
204-337-6
|
119-61-9
|
Carc. 1B
|
H350
|
GHS08
Dgr
|
H350”
|
|
|
|
“606-154-00-0
|
hinoklamīns (ISO); 2-amino-3-hlor-1,4-naftohinons
|
220-529-2
|
2797-51-5
|
Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H361d
H302
H373 (asinsrites sistēma, nieres)
H319
H317
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H351
H361d
H302
H373 (asinsrites sistēma, nieres)
H319
H317
H410
|
|
perorāli:
ATE = 500 mg/kg ķm
M = 10
M = 10”
|
|
“607-756-00-6
|
ekso-1,7,7-trimetilbiciklo[2.2.1]hept-2-ilakrilāts; izobornilakrilāts
|
227-561-6
|
5888-33-5
|
Skin Sens. 1A
|
H317
|
GHS07
Wng
|
H317”
|
|
|
|
“607-757-00-1
|
daminozīds (ISO); 4-(2,2-dimetilhidrazīn)-4-oksobutānskābe; N-dimetilaminosukcīnamīnskābe
|
216-485-9
|
1596-84-5
|
Carc. 2
|
H351
|
GHS08
Wng
|
H351”
|
|
|
|
“607-758-00-7
|
4,4′-oksidi(benzolsulfonohidrazīds)
|
201-286-1
|
80-51-3
|
Self-react. D
Aquatic Acute 1
Aquatic Chronic 1
|
H242
H400
H410
|
GHS02
GHS09
Dgr
|
H242
H410
|
|
M = 1
M = 1”
|
|
“607-759-00-2
|
toluol-4-sulfonohidrazīds
|
216-407-3
|
1576-35-8
|
Self-react. D
|
H242
|
GHS02
Dgr
|
H242”
|
|
|
|
“607-760-00-8
|
2-[N-etil-4-[(5-nitrotiazol-2-il)azo]-m-toluidīn]etilacetāts; C.I. dispersais zilais 124
|
239-203-6
|
15141-18-1
|
Skin Sens. 1A
|
H317
|
GHS07
Wng
|
H317
|
|
Skin Sens. 1A; H317: C ≥ 0,001 %”
|
|
“607-761-00-3
|
perfluorheptānskābe tridekafluorheptānskābe
|
206-798-9
|
375-85-9
|
Repr. 1B
STOT RE 1
|
H360D
H372 (aknas)
|
GHS08
Dgr
|
H360D
H372 (aknas)”
|
|
|
|
“607-762-00-9
|
metil N-(izopropoksikarbonil)-L-valil-3RS)-3(4-hlorfenil)-β-alanināts valifenalāts
|
-
|
283159-90-0
|
Carc. 2
Aquatic Chronic 2
|
H351
H411
|
GHS08
GHS09
Wng
|
H351
H411”
|
|
|
|
“607-763-00-4
|
6-[C12-18-alkil-(sazarotas, nepiesātinātas)-2,5-dioksopirolidīn-1-il]heksānskābes nātrija un tris(2-hidroksietil)amonija sāļi
|
-
|
-
|
Repr. 1B
Eye Irrit. 2
|
H360FD
H319
|
GHS08
GHS07
Dgr
|
H360FD
H319”
|
|
|
|
“607-764-00-X
|
6-[(C10-C13)-alkil-(sazarota, nepiesātināta)-2,5-dioksopirolidīn-1-il]heksānskābe
|
-
|
2156592-54-8
|
Repr. 1B
Eye Irrit. 2
|
H360FD
H319
|
GHS08
GHS07
Dgr
|
H360FD
H319”
|
|
|
|
“607-765-00-5
|
6-[C12-18-alkil-(sazarota, nepiesātināta)-2,5-dioksopirolidīn-1-il]heksānskābe
|
-
|
-
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD”
|
|
|
|
“613-341-00-0
|
klofentezīns (ISO); 3,6-bis(o-hlorfenil)-1,2,4,5-tetrazīns
|
277-728-2
|
74115-24-5
|
Aquatic Chronic 1
|
H410
|
GHS09
Wng
|
H410
|
|
M = 1”
|
|
“613-342-00-6
|
teofilīns; 1,3-dimetil-3,7-dihidro-1H-purīn-2,6-dions
|
200-385-7
|
58-55-9
|
Repr. 1B
|
H360D
|
GHS08
Dgr
|
H360D”
|
|
|
|
“613-343-00-1
|
piridalils (ISO); 2,6-dihlor-4-(3,3-dihloraliloksi)fenil 3-[5-(trifluormetil)-2-piridiloksi]propil ēteris
|
-
|
179101-81-6
|
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H317
H400
H410
|
GHS07
GHS09
Wng
|
H317
H410
|
|
M = 1 000
M = 100”
|
|
“613-344-00-7
|
Piridīn-2-tiola 1-oksīda nātrija sāls; nātrija piritions;
|
223-296-5;
240-062-8
|
3811-73-2;
15922-78-8
|
Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 2
|
H331
H311
H302
H372 (nervu sistēma)
H315
H319
H317
H400
H411
|
GHS06
GHS08
GHS09
Dgr
|
H331
H311
H302
H372 (nervu sistēma)
H315
H319
H317
H410
|
EUH070
|
ieelpojot:
ATE = 0,5 mg/L (putekļi vai aerosoli)
dermāli:
ATE = 790 mg uz kg ķermeņa masas
perorāli:
ATE = 500 mg/kg ķm
M = 100”
|
|
“613-345-00-2
|
1,3,5-triazīn-2,4,6-triamīns
melamīns
|
203-615-4
|
108-78-1
|
Carc. 2
STOT RE 2
|
H351
H373 (urīnceļi)
|
GHS08
Wng
|
H351
H373 (urīnceļi)”
|
|
|
|
“615-046-00-2
|
1,3-bis(1-izocianāt-1-metiletil)benzols; [m-TMXDI]
|
220-474-4
|
2778-42-9
|
Resp. Sens. 1
Skin Sens. 1A
|
H334
H317
|
GHS08
Dgr
|
H334
H317”
|
|
|
|
“615-047-00-8
|
1,3-bis(izocianātmetil)benzols; [m-XDI]
|
222-852-4
|
3634-83-1
|
Resp. Sens. 1
Skin Sens. 1A
|
H334
H317
|
GHS08
Dgr
|
H334
H317
|
|
Skin Sens. 1A; H317: C ≥ 0,001 %”
|
|
“615-048-00-3
|
2,4,6-triizopropil-m-fenilēndiizocianāts
|
218-485-4
|
2162-73-4
|
Resp. Sens. 1
Skin Sens. 1
|
H334
H317
|
GHS08
Dgr
|
H334
H317”
|
|
|
|
“615-049-00-9
|
1,5-naftalēna diizocianāts
[kas satur < 0,1 % masas procentus daļiņu, kuru aerodinamiskais diametrs nesasniedz 50 μm]
|
221-641-4
|
3173-72-6
|
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
|
H335
H315
H319
H334
H317
H412
|
GHS07
GHS08
Dgr
|
H335
H315
H319
H334
H317
H412”
|
|
|
|
“615-050-00-4
|
1,5-naftalēna diizocianāts
[kas satur ≥ 0,1 % masas procentus daļiņu, kuru aerodinamiskais diametrs nesasniedz 50 μm]
|
221-641-4
|
3173-72-6
|
Acute Tox. 2
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3
|
H330
H335
H315
H319
H334
H317
H412
|
GHS06
GHS08
Dgr
|
H330
H335
H315
H319
H334
H317
H412
|
|
ieelpojot:
ATE = 0,27 mg/L (putekļi vai aerosoli)”
|
|
“616-237-00-3
|
fluopikolīds (ISO); 2,6-dihlor-N-[3-hlor-5-(trifluormetil)-2-piridilmetil]benzamīds
|
-
|
239110-15-7
|
Repr. 2
|
H361d
|
GHS08
Wng
|
H361d”
|
|
|
|
“616-238-00-9
|
N-(2-nitrofenil)fosfora triamīds
|
477-690-9
|
874819-71-3
|
Repr. 1B
STOT RE 2
|
H360Fd
H373 (nieres)
|
GHS08
Dgr
|
H360Fd
H373 (nieres)”
|
|
|
|
“616-239-00-4
|
N-(5-hlor-2-izopropilbenzil)-N-ciklopropil-3-(difluormetil)-5-fluor-1-metil-1H-pirazol-4-karboksamīds; izofluciprāms
|
-
|
1255734-28-1
|
Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
|
H361f
H332
H317
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H361f
H332
H317
H410
|
|
ieelpojot:
ATE = 2,2 mg/L (putekļi vai aerosoli)
M = 10
M = 1”
|
|
“616-240-00-X
|
3-(difluormetil)-1-metil-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahidro-9-izopropil-1,4-metanonaftalēn-5-il]pirazol-4-karboksamīda un 3-(difluormetil)-1-metil-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahidro-9-izopropil-1,4-metanonaftalēn-5-il]pirazol-4-karboksamīda [ar relatīvo saturu ≥ 78 % syn izomēri ≤ 15 % antiizomēri] reakcijas masa; izopirazāms
|
-
|
881685-58-1
|
Carc. 2
Repr. 1B
Skin Sens. 1B
Aquatic Acute 1 Aquatic Chronic 1
|
H351
H360D
H317
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H351
H360D
H317
H410
|
|
Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10”
|
|
“650-058-00-1
|
Margozas ekstrakts [ar ūdeni ekstrahēts no Azadirachta indica sēklām un tālāk apstrādāts ar organiskiem šķīdinātājiem]
|
283-644-7
|
84696-25-3
|
Repr. 2
Skin Sens. 1
Aquatic Chronic 1
|
H361d
H317
H410
|
GHS08
GHS07
GHS09
Wng
|
H361d
H317
H410
|
|
M = 10”;
|
|